The most widely used high-dose chemotherapy (HDC) before autologous stem cell transplant (ASCT) is BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [1, 2], which is considered the gold standard both in United States and Europe [3, 4]. However, carmustine has been often substituted by other molecules due to its difficult supplying and high costs [3, 5]. In Italy, the most frequently used alternative regimen is FEAM (fotemustine, etoposide, cytarabine, melphalan), in which carmustine is replaced by fotemustine, a third-generation chloroethyl-nitrosourea with ability to cross the blood–brain barrier and a more favorable pulmonary toxicity profile, however not available in all European countries [6]. Even though only two phase-2 studies have been until now published [7, 8], the Italian Regulatory Agency for medical products granted reimbursement of fotemustine by the National Health Service as component of FEAM regimen. Based on these considerations, we aimed to investigate in a retrospective study the comparison between BEAM and FEAM regimen in terms of efficacy and safety in lymphoma patients undergoing ASCT.

. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant / Marchesi, F.; Capria, S.; Giannarelli, D.; Trisolini, S. M.; Ansuinelli, M.; Caputo, M. D.; Serrao, A.; Gumenyuk, S.; Renzi, D.; Pupo, L.; Palombi, F.; Provenzano, I.; Di Rocco, A.; Pisani, F.; Romano, A.; Spadea, A.; Papa, E.; Canfora, M.; Cantonetti &, M.; Mengarelli, A.. - In: BONE MARROW TRANSPLANTATION. - ISSN 1476-5365. - (2018). [10.1038/s41409-018-0120-x]

. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant.

S. Capria;M. Ansuinelli;A. Serrao;A. Di Rocco;
2018

Abstract

The most widely used high-dose chemotherapy (HDC) before autologous stem cell transplant (ASCT) is BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [1, 2], which is considered the gold standard both in United States and Europe [3, 4]. However, carmustine has been often substituted by other molecules due to its difficult supplying and high costs [3, 5]. In Italy, the most frequently used alternative regimen is FEAM (fotemustine, etoposide, cytarabine, melphalan), in which carmustine is replaced by fotemustine, a third-generation chloroethyl-nitrosourea with ability to cross the blood–brain barrier and a more favorable pulmonary toxicity profile, however not available in all European countries [6]. Even though only two phase-2 studies have been until now published [7, 8], the Italian Regulatory Agency for medical products granted reimbursement of fotemustine by the National Health Service as component of FEAM regimen. Based on these considerations, we aimed to investigate in a retrospective study the comparison between BEAM and FEAM regimen in terms of efficacy and safety in lymphoma patients undergoing ASCT.
2018
lymphoma, autologous stem cell transplantation, beam
01 Pubblicazione su rivista::01a Articolo in rivista
. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant / Marchesi, F.; Capria, S.; Giannarelli, D.; Trisolini, S. M.; Ansuinelli, M.; Caputo, M. D.; Serrao, A.; Gumenyuk, S.; Renzi, D.; Pupo, L.; Palombi, F.; Provenzano, I.; Di Rocco, A.; Pisani, F.; Romano, A.; Spadea, A.; Papa, E.; Canfora, M.; Cantonetti &, M.; Mengarelli, A.. - In: BONE MARROW TRANSPLANTATION. - ISSN 1476-5365. - (2018). [10.1038/s41409-018-0120-x]
File allegati a questo prodotto
File Dimensione Formato  
Marchesi_BEAM-FEAM_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 517.67 kB
Formato Adobe PDF
517.67 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1416564
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact